CoChat

Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health‐related quality of life. A prospective cohort study in primary care

Open access
Hajos, T. R. S., Pouwer, F., de Grooth, R., Holleman, F., Twisk, J. W. R., Diamant, M., Snoek, F. J. · 2011 · Diabetic Medicine
Cited by 37

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Diabet. Med. 28, 1096–1102 (2011) Aims To study prospectively the impact of initiating insulin glargine in suboptimally controlled insulin‐naïve patients with Type 2 diabetes on health‐related quality of life in relation to glycaemic control. Methods Insulin‐naïve Dutch patients with Type 2 diabetes in suboptimal glycaemic control (HbA 1c > 53 mmol/mol; 7%) on maximum dose of oral glucose‐lowering medications were included from 363 primary care practices (n = 911). Patients started insulin glargine and were followed up for 6 months. At baseline (start insulin therapy), 3 and 6 months, HbA 1c was measured and patients completed self‐report health‐related quality of life measures, including emotional well‐being (World Health Organization‐5 well‐being index), fear of hypoglycaemia (Hypoglycaemia Fear Survey) and diabetes symptom distress (Diabetes Symptom Checklist—revised). Data were analysed using generalized estimating equations analysis. Results HbA 1c (mmol/mol; %) decreased from 69 ± 16; 8.5 ± 1.7 to 60 ± 11; 7.6±1.0 and 57 ± 11; 7.3 ± 1.0 at 3 and 6 months, respectively (P < 0.001). Pre‐insulin BMI (kg/m 2) was 30 ± 5.7, which remained stable at 3 months (30 ± 5.8) and increased to 31 ± 5.9 at 6 months (P = 0.004); no significant changes in self‐reported symptomatic and severe hypoglycaemia were observed, while nocturnal hypoglycaemia slightly decreased. The Hypoglycaemia Fear Survey score decreased from 14.6 ± 16.2 to 12.1 ± 15.2 and 10.8 ± 14.4 at 3 and 6 months, respectively (P < 0.001). The Diabetes Symptom Checklist—revised score decreased from 15 ± 14 to 10 ± 12 and 10 ± 13 (P < 0.001), with most pronounced reductions in hyperglycaemic symptoms and fatigue. The World Health Organization‐5 score increased from 57 ± 25.3 to 65 ± 21.6 at 3‐month follow‐up and 67 ± 21.8 at 6‐month follow‐up (P < 0.001). Conclusions Results of this observational study demonstrate combined glycaemic and health‐related quality of life benefits of initiating insulin glargine in patients with Type 2 diabetes in routine primary care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2011.03329.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 37

Metadata

Authors
Hajos, T. R. S., Pouwer, F., de Grooth, R., Holleman, F., Twisk, J. W. R., Diamant, M., & Snoek, F. J.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2011-08-15
Volume
28
Issue
9
Pages
1096-1102
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1582120475
Cited by
37
References
7
FWCI
3.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health‐related quality of life. A prospective cohort study in primary care. https://app.cochat.ai/papers/10.1111/j.1464-5491.2011.03329.x
The paper
Hajos, T. R. S., Pouwer, F., de Grooth, R., Holleman, F., Twisk, J. W. R., Diamant, M., & Snoek, F. J. (2011). Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health‐related quality of life. A prospective cohort study in primary care. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2011.03329.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.